

In the Specification:

Please amend the specification as follows:

Please delete the paragraph on page 32, line 21, to page 33, line 4, and replace it with the following paragraph:

We have now synthesized the D-form of the 6 parent 12-13 amino acid peptides discussed above as Sequence Group B (all L-forms) as showing superior A β amyloid inhibitory activity. Since we earlier tested the L-form of each of the 6 laminin derived peptides, we chose to synthesize the D-amino acid form of the same 6 laminin derived peptides. Those D-form amino acids synthesized are: DP1) AG73 (RKRLQVQLSIRT) (SEQ ID NO: 1), DP2) A13 (RQVFQVAYIIKA) (SEQ ID NO: 3), DP3) HA3G76 (YLSKGRLVFALG) (SEQ ID NO: 8), DP4) A4G82 (TLFLAHGRLVFM) (SEQ ID NO: 11), DP5) A5G81 (AGQWHRVSVRWG) (SEQ ID NO: 15), and DP6) A5G101 (DGRWHRVAVIGM) (SEQ ID NO: 18). The D amino acid form of these peptides is believed to offer some therapeutic advantage over L-form peptides, since the D amino acid peptides are known to be more resistant to *in vivo* protease degradation. In addition, the reverse sequences (DP13-18) of all 6 D-form peptides described above were also synthesized to determine if reversing the sequence alters potential A β amyloid inhibitory activity. Lastly, a group of another 6 D amino acid 12-13 mer peptides (DP7-12) were also synthesized, and these represents 6 additional laminin derived peptides (also already tested in L amino acid form) that were only somewhat less effective than the first 6 peptides described above, still maintaining >25% A β fibril disrupting ability.

Please delete the paragraph on page 33, lines 8-11, and replace it with the following paragraph:

For example, representative DP1 D-AG73 peptide truncations (the resulting 7 L- or D-amino acid peptides synthesized and tested for amyloid inhibitory activity) are RKRLQVQ(Y) (SEQ ID NO: 66), KRLQVQL(Y) (SEQ ID NO: 67), RLQVQLS(Y) (SEQ ID NO: 68), LQVQLSI(Y) (SEQ ID NO: 69), QVQLSIR(Y) (SEQ ID NO: 70) and, VQLSIRT(Y) (SEQ ID NO: 71).

Please delete the paragraph on page 33, lines 12-14, and replace it with the following paragraph:

For example, for DP2 D-A13 peptide truncation, a resulting (7 L- or D-amino acid) peptides synthesized and tested for amyloid inhibitory activity is RQVFQVA (SEQ ID NO: 72), QVFQVAY (SEQ ID NO: 73), VFQVAYI (SEQ ID NO: 74), FQVAYII (SEQ ID NO: 75), QVAYIII (SEQ ID NO: 76), VAYIIIK (SEQ ID NO: 77), and AYIIIKA (SEQ ID NO: 78).

Please delete the paragraph on page 33, lines 15-17, and replace it with the following paragraph:

For example, for DP3 D-HA3G76 peptide truncation, a resulting (7 L- or D-amino acid) peptides synthesized and tested for amyloid inhibitory activity is YLSKGRL(Y) (SEQ ID NO: 79), LSKGRLV(Y) (SEQ ID NO: 80), SKGRLVF(Y) (SEQ ID NO: 81), KGRLVFA(Y) (SEQ ID NO: 82), GRLVFAL(Y) (SEQ ID NO: 83), and RLVFALG(Y) (SEQ ID NO: 84).

Please delete the paragraph on page 33, lines 18-21, and replace it with the following paragraph:

For example, for DP4 D-A4G82 peptide truncation, a resulting (7 L- or D-amino acid) peptides synthesized and tested for amyloid inhibitory activity is DP38 TLFLAHG(Y) (SEQ ID NO: 85), DP39 LFLAHGR(Y) (SEQ ID NO: 86), DP40 FLAHGRL(Y) (SEQ ID NO: 87), DP41 LAHGRLV(Y) (SEQ ID NO: 88), DP42 AHGRLVF(Y) (SEQ ID NO: 89), and DP43 HGRLVFM(Y) (SEQ ID NO: 90).

Please delete the paragraph on page 33, lines 22-25, and replace it with the following paragraph:

For example, for DP5 D-A5G81 peptide truncation, a resulting (7 L- or D-amino acid) peptides synthesized and tested for amyloid inhibitory activity is DP 26 AGQWHRV(Y) (SEQ ID NO: 91), DP27 GQWHRVS(Y) (SEQ ID NO: 92), DP28 QWHRVSV(Y) (SEQ ID NO: 93), DP29 WHRVSVR(Y) (SEQ ID NO: 94), DP30 HRVSVRW(Y) (SEQ ID NO: 95), and DP31 RVSVRWG(Y) (SEQ ID NO: 96).

Please delete the paragraph on page 33, lines 26-29, and replace it with the following paragraph:

For example, for DP6 D-A5G101peptide truncation, a resulting (7 L- or D-amino acid) peptides synthesized and tested for amyloid inhibitory is DP 32 DGRWHRV(Y) (SEQ ID NO: 97), DP33 GRWHRVA(Y) (SEQ ID NO: 98), DP34 RWHRVAV(Y) (SEQ ID NO: 99), DP35 WHRVAVI(Y) (SEQ ID NO: 100), DP36 HRVAVIM(Y) (SEQ ID NO: 101), and DP37 RVAVIMG(Y) (SEQ ID NO: 102).